Literature DB >> 11201849

Epitope analysis of the human thyrotropin (TSH) receptor using monoclonal antibodies.

Y Oda1, J Sanders, M Evans, A Kiddie, A Munkley, C James, T Richards, J Wills, J Furmaniak, B R Smith.   

Abstract

A panel of thyrotropin (TSH) receptor (TSHR) monoclonal antibodies (mAbs), produced using highly purified Chinese hamster ovary (CHO) cell-produced TSHR, has been used to study TSHR structure. All 41 mAbs recognized full-length TSHR containing complex carbohydrate (120 kDa), and 40 mAbs recognized full-length precursor-containing high mannose sugars (100 kDa). The mAbs also recognized TSHR cleavage products with three types of reactivity: type 1 mAbs reacting with bands at 70 kDa and 58 kDa, type 2 with bands at 70 kDa and 52 kDa, and type 3 with bands at 52 kDa and 40 kDa. Deglycosylation studies showed that the 70-kDa and 58-kDa bands contained complex carbohydrate, whereas the 52-kDa and 40-kDa bands were unglycosylated. These results are consistent with TSHR cleavage occurring at two sites. Cleavage at both sites gives rise to glycosylated A subunit (58 kDa) corresponding to the extracellular domain of the receptor and nonglycosylated B subunit (40 kDa) corresponding to the C-terminal transmembrane domain. Cleavage only at site 1 gives rise to the 58-kDa A subunit and a large B subunit (52 kDa). Cleavage only at site 2 gives rise to a large A subunit (70 kDa) and the B subunit (40 kDa). Four of the mAbs inhibited 125I-labeled TSH binding to solubilized full-length TSHR. TSH binding was inhibited by (a) two type 3 mAbs reactive with the N-terminal region of the B subunit (epitopes between amino acids 381 and 385 and between 380 and 418, respectively) and (b) two type 2 mAbs reactive with epitopes on the A subunit (between amino acids 246 and 260). These results together with previous studies on the direct binding of TSH to the TSHR A subunit suggest that at least two distinct regions of the TSHR sequence, including one region on the A subunit and one region on the B subunit, fold together to form part of a complex TSH binding site.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11201849     DOI: 10.1089/thy.2000.10.1051

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  9 in total

1.  Cleavage of the thyrotropin receptor.

Authors:  N M Islam; C L Hew; V Kaczur; N R Farid
Journal:  J Endocrinol Invest       Date:  2001-11       Impact factor: 4.256

2.  A monoclonal thyroid-stimulating antibody.

Authors:  Takao Ando; Rauf Latif; Alla Pritsker; Thomas Moran; Yuji Nagayama; Terry F Davies
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

3.  Human TSH receptor ligands as pharmacological probes with potential clinical application.

Authors:  Susanne Neumann; Bruce M Raaka; Marvin C Gershengorn
Journal:  Expert Rev Endocrinol Metab       Date:  2009-11-01

4.  Epitope recognition in HLA-DR3 transgenic mice immunized to TSH-R protein or peptides.

Authors:  Hidefumi Inaba; Leonard Moise; William Martin; Anne S De Groot; Joe Desrosiers; Ryan Tassone; George Buchman; Takashi Akamizu; Leslie J De Groot
Journal:  Endocrinology       Date:  2013-04-16       Impact factor: 4.736

Review 5.  TSH receptor autoantibodies.

Authors:  Krzysztof Michalek; Syed A Morshed; Rauf Latif; Terry F Davies
Journal:  Autoimmun Rev       Date:  2009-03-27       Impact factor: 9.754

6.  Antibodies to TSH-receptor in thyroid autoimmune disease interact with monoclonal antibodies whose epitopes are broadly distributed on the receptor.

Authors:  W B Minich; C Lenzner; N G Morgenthaler
Journal:  Clin Exp Immunol       Date:  2004-04       Impact factor: 4.330

Review 7.  Blocking type TSH receptor antibodies.

Authors:  Jadwiga Furmaniak; Jane Sanders; Bernard Rees Smith
Journal:  Auto Immun Highlights       Date:  2012-03-21

Review 8.  Thyrotropin Receptor Epitope and Human Leukocyte Antigen in Graves' Disease.

Authors:  Hidefumi Inaba; Leslie J De Groot; Takashi Akamizu
Journal:  Front Endocrinol (Lausanne)       Date:  2016-08-23       Impact factor: 5.555

9.  Engineering Multi-Walled Carbon Nanotube Therapeutic Bionanofluids to Selectively Target Papillary Thyroid Cancer Cells.

Authors:  Idit Dotan; Philip J R Roche; Miltiadis Paliouras; Elliot J Mitmaker; Mark A Trifiro
Journal:  PLoS One       Date:  2016-02-22       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.